Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity [PDF]
Biochemical Journal, 1998 Cytochrome P-450 CYP2D6, human debrisoquine hydroxylase, metabolizes more than 30 prescribed drugs, the vast majority of which are small molecules containing a basic nitrogen atom. In contrast, the similar mouse protein Cyp2d-9 was first characterized as a testosterone 16α-hydroxylase. No common substrates have been reported for the two enzymes.
Gillian Smith +2 more
exaly +7 more sources
Association of polymorphism of CYP2D6 and CYP2C9 genes encoding P-450 proteins of cytochrome with arterial hypertension [PDF]
Саратовский научно-медицинский журнал, 2012 Gene polymorphisms of cytochrome P-450 CYP2 encoding proteins of cytochrome P-450 are essential forantihy-pertensive drugs metabolism. Purpose: We study the associations of functionally defective allele variants of CYP2D6 gene and CYP2C9 gene with the ...
Saratsev A.V. +7 more
doaj +2 more sources
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses. [PDF]
PLoS ONE, 2016 Although Plasmodium vivax relapses are classically associated with hypnozoite activation, it has been proposed that a proportion of these cases are due to primaquine (PQ) treatment failure caused by polymorphisms in cytochrome P-450 2D6 (CYP2D6).
Ana Carolina Rios Silvino +8 more
doaj +4 more sources
Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study. [PDF]
PLoS Neglected Tropical DiseasesBackgroundPrimaquine (PQ) is the only widely available drug that eliminates latent hypnozoites, thereby preventing relapses of Plasmodium vivax malaria. Because PQ biotransformation mediated by the cytochrome P-450 (CYP) isoenzyme CYP2D6 is required for ...
Rodrigo M Corder +8 more
doaj +2 more sources
Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy. [PDF]
Journal of Neurology, Neurosurgery and Psychiatry, 1995 Oliver Bandmann, Gregor K Wenning
exaly +3 more sources
Association of cytochrome P-450 n D6(CYP2D6) gene polymorphism with some diseases.
The Japanese Journal of Pharmacology, 1993 Yutaka Tsuneoka
exaly +2 more sources
Frontiers in Pharmacology, 2022 Clinical practice environments without in-house pharmacogenetic testing often rely on commercial laboratories, especially in the setting of pharmacogenetic testing intended to guide psychotropic use.
Christopher Blazy +3 more
doaj +1 more source
Pharmacology Research & Perspectives, 2023 Small studies suggest that amiodarone is a weak inhibitor of cytochrome P450 (CYP) 2D6. Inhibition of CYP2D6 leads to increases in concentrations of drugs metabolized by the enzyme, such as metoprolol. Considering that both metoprolol and amiodarone have
Sabrina Robert +11 more
doaj +1 more source
Toxins, 2022 Cytochrome P-450 (CYP) enzymes have a key role in the metabolism of xenobiotics of food origin, and their highly polymorphic nature concurs with the diverse inter-individual variability in the toxicokinetics (TK) and toxicodynamics (TD) of food chemicals.
Jean Lou C. M. Dorne +5 more
doaj +1 more source
CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People
Frontiers in Pharmacology, 2020 The aim of this study was to provide dose recommendations for risperidone in Asian people based on cytochrome P450 enzyme CYP2D6 genotype. First, we investigated the influence of CYP2D6 polymorphism on the pharmacokinetics of risperidone in Chinese ...
Yuanxia Cui +14 more
doaj +1 more source